|
Post by tchalaa on May 25, 2016 8:34:54 GMT -5
Yes my question was the last one. There was some applause but not sure if that was for me or for Matt. Perhaps it because it was the last question. You sound like our gone genius AL Mann (RIP)
|
|
|
Post by lakers on May 25, 2016 10:20:58 GMT -5
Meanwhile Dance Pharma already has a Chinese Partner. Quite honestly they better get their act together by ADA as they seem to operate as if they are equivalent in size to a giant pharma like Sanofi, and I am NOT impressed at the speed they are moving. They knew since last year that Sanofi was abandoning them. they could have done ALL this work and lined up other suitors by April of this year. Anybody ask him what those sales milestones are that allows Matt to buy a million shares at <$1 ? Is it 1000, 10000, 100000 or 1M scripts ? Dance Biopharm Announces Joint Venture with Harmony Asset for the Development of Inhaled Insulin in Multiple Countries in Asia SAN FRANCISCO, Oct. 15, 2013 /PRNewswire/ -- Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced that it has entered into a joint venture with Harmony Asset for the development of inhaled insulin in China and other Asian countries (excluding Japan). Under the joint venture, Harmony will cover the majority of the development expenses in most of the specified regions and will receive ownership in those territories commensurate with the level of expenses paid. The joint venture will enable Dance Biopharm to significantly expedite its regulatory, manufacturing, and commercial partnering efforts in China. "We are excited to partner with Harmony on this joint venture and believe that Harmony's strong expertise in China and extensive connections among China regulatory, manufacturing, and pharmaceutical business leaders will be invaluable as we move toward product approval of Adagio inhaled insulin. With the help of Harmony, we have already begun a process to select a commercialization partner for mainland China," stated John Patton, Ph.D., chairman and chief executive officer of Dance Biopharm. "We are in active communication with regulatory authorities in Europe and the United States regarding our path to approval for Adagio, and this joint venture represents an important part of our strategy to pursue product approval with multiple regulatory authorities in parallel in order to get this product to millions of diabetic patients in need, worldwide." "We are very excited with this opportunity to partner with Dance. We believe this company holds the key to improving the well-being and lifestyle of millions of diabetic patients everywhere," stated Augustine Chow, Ph.D., chief executive officer of Harmony Asset Limited. "We are thrilled to be bringing these amazing products to Asia Pacific, and we are committed to taking Adagio through regulatory authorities and identifying strategic partners in each country as soon as practical." The joint venture entered into by Dance and Harmony will focus on the development and commercialization of inhaled insulin in multiple countries, of which the major ones are China, Korea, India, Indonesia and Australia. The joint venture, which is majority owned by Harmony, will be governed by a board of directors comprised of an even number of representatives from each company. The objective of the joint venture is to pursue development of the inhaled insulin products and to navigate the products through foreign regulatory processes and then into commercialization in the specified regions. Where desired, the joint venture will seek regional partners for commercialization. About Adagio™, a Second-generation Inhaled Insulin Product Dance Biopharm's Adagio is a novel second-generation inhaled insulin product in development that could resolve issues inherent in the first-generation inhaled insulin products, which were known to be safe and effective yet uneconomical and cumbersome. The liquid formulation of natural human insulin is dispensed through a small, silent, handheld electronic aerosol device, intended to deliver the patient's individualized dose of insulin in one to three breaths at mealtime. Dance has chosen to develop a liquid formulation of insulin instead of a dry powder with the goals of lowering manufacturing costs, eliminating cough, and facilitating ease-of-use. Adagio is currently in clinical trials and is in preparation for pivotal development. The first clinical trial was completed in Germany, and the company has conducted an extensive scientific advice process in Europe, which has resulted in an abbreviated development plan there. The company is actively engaged in discussions with the U.S. Food and Drug Administration (FDA) and is incorporating FDA input into clinical development plans for Adagio. www.prnewswire.com/news-releases/dance-biopharm-announces-joint-venture-with-harmony-asset-for-the-development-of-inhaled-insulin-in-multiple-countries-in-asia-227792911.html
|
|
|
Post by kc on May 25, 2016 10:35:18 GMT -5
Interesting video on their website. But again it's cumbersome compared to Afrezza / Technosphere. Then you also have to carry around an liquid insulin. Oh and its not FDA approved yet. Its only investigational.
|
|
|
Post by Chris-C on May 28, 2016 11:30:57 GMT -5
KC Thanks for reposting the video, which I watched a few days ago and on which I am only now getting around to comment. I have three observations based on the video (which, IMO, represents another solid example of Matt's commitment to have the company show greater transparency to retail shareholders.)
1. The first observation is that I had a much different feeling about the company (greater confidence and optimism) after watching the video than I had from reading the posts here. Clearly each person witnessing an event will take away a different perspective; but being there provides so much more context that can never be captured adequately in written descriptions, that are always filtered through the lens and perspectives and attitudes of the person doing the reporting.
2. I had a different feeling about Orlofsky's comments after watching the video than I had gotten from the board descriptions. Part of the issue with the Q&A session generally, it seems, stemmed from the positioning of the hand held remote microphone, carried by a staffer who may have been under instruction to retain control of it. Mr. Orlofsky's comments were soft spoken, but he appeared to me to be articulate, in clear control of his faculties (he's 92 years old, I believe), and genuine. Who knows what transpired off-line between Mr. Orlofsky and MNKD board members, at least with respect to exchanging contact information and arranging meetings? I don't hold an expectation about outcomes from his comment; but I do think it illustrates that there is, and will continue to be, outside investment interest in this company and what it has to offer. I think it has been factually confirmed that Mr Orlofsky did indeed serve on an aerospace company board of directors with Al Mann. (I did some sleuthing and was entertained by the history of that company, which continues manufacturing small aircraft).
3. My impression is that there has been a great deal of work accomplished since Mr. Pfeffer was appointed CEO and it appears he has assembled a competent team under very difficult circumstances- not unlike changing the tires on a moving bus with one eye on the gas gauge and a rapidly diminishing fuel supply. Overall, I was impressed; and I think Matt should be given credit for the significant changes he has made. I did not sense a leadership team or board with any sense of panic, but rather one exhibiting a tone of quiet confidence in a well considered transition plan.
I'm still holding all my shares, but I'm closer to acquiring more and will do so at the first sign of success with the new strategy led by Mike. No one is happy about dilution, but the Sanofi fiasco made it necessary. Looking back, an offering when the PPS was over $5 would have made much more sense; but hindsight is always 20/20. Matt doesn't have to take the rap on that one, Hakan does; which may partially explain why he is gone.
GLTAL, Chris C
|
|
|
Post by mnkdfann on May 28, 2016 19:36:44 GMT -5
Looking back, an offering when the PPS was over $5 would have made much more sense; but hindsight is always 20/20. I wasn't seriously following MNKD back then. So I will ask, do we know that they did not explore an offering when the PPS was over $5? Perhaps they investigated doing one, but lacked sufficient buyers at that price?
|
|
|
Post by formermnkdemployee on May 28, 2016 21:19:21 GMT -5
I was working at the company 10 years ago and they were looking for partners then.
|
|
|
Post by kc on May 28, 2016 21:48:28 GMT -5
I was working at the company 10 years ago and they were looking for partners then. But the didn't have a FDA Approved drug at that time. They do today. 12 to 24 months we we'll see if we are winners or big losers
|
|
|
Post by mnkdfann on May 28, 2016 22:23:33 GMT -5
I was working at the company 10 years ago and they were looking for partners then. Perhaps I misunderstand your post, but I think looking for partners and looking for buyers to support an offering are two different things. I suspect they would have loved to do an offering when the PPS was above $5, but the market / banks / investment community were simply not interested. But this is just a guess.
|
|
|
Post by agedhippie on May 29, 2016 8:42:56 GMT -5
I was working at the company 10 years ago and they were looking for partners then. Perhaps I misunderstand your post, but I think looking for partners and looking for buyers to support an offering are two different things. I suspect they would have loved to do an offering when the PPS was above $5, but the market / banks / investment community were simply not interested. But this is just a guess. More likely that with the Sanofi partnership in place they thought they had a whole lot more time than they did. If they had known that was coming they would have handled the debt debacle last year (that still annoys me) differently and taken more dilution to preserve the cash. Equally they would not have tried to impose stupid conditions on the TASE sale and would have taken a lot more there as well.
|
|
|
Post by cretin11 on May 29, 2016 21:52:25 GMT -5
Just my perspective, but it seemed back when PPS was around $5, the prevailing mood among most of "us" around here was that $5 was a dip and we woulda been pretty upset at dilution at such a low price (or so we thought at the time). Did Matt et al. share those feelings of optimism? Maybe he shoulda known better, but I won't throw stones if he didn't, since I sure didn't.
|
|